GLP-1 clinical trials in Missouri: 21 recruiting now

21 GLP-1 clinical trials are recruiting at 28 sites in 8 cities across Missouri. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Missouri

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   1 site in Missouri

   • University of Missouri-Columbia, Columbia. 833-970-0046

2. Impact GLP-1 Agonists Following Bariatric

   Phase 4. Run by University of Missouri-Columbia. Registry number NCT06132477.

   A study testing whether a GLP-1 medicine can help people with obesity lose weight.

   Who can join. Adults 18+, have obesity, BMI 30+.

   1 site in Missouri

   • University of Missouri Hospital, Columbia. 573-882-5609

3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   3 sites in Missouri

   • Clinical Research Professionals, Chesterfield. 833-602-2368
   • ObjectiveHealth-GI Associates Research, Columbia. 833-602-2368
   • Kansas City Research Institute, Kansas City. 833-602-2368

4. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

   2 sites in Missouri

   • ObjectiveHealth-GI Associates Research, Columbia. 833-602-2368
   • Kansas City Research Institute, Kansas City. 833-602-2368

5. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

   Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

   2 sites in Missouri

   • StudyMetrix Research, City of Saint Peters. 636-387-5100
   • AMR Clinical, Kansas City

6. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   2 sites in Missouri

   • Clinical Research Professionals, Chesterfield
   • Amicis Centers of Clinical Research, St Louis

7. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

   Phase 3. Run by AstraZeneca. Registry number NCT07662213.

   A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

   Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

   2 sites in Missouri

   • Research Site, Jefferson City
   • Research Site, Kansas City

8. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 6 to 17, have obesity.

   1 site in Missouri

   • Sundance Clinical Research, St Louis. 314-567-3377

9. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 12 to 17, have obesity.

   1 site in Missouri

   • Sundance Clinical Research, St Louis

10. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Missouri

    • Washington University School of Medicine, St Louis

11. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Missouri

    • Washington University School of Medicine, St Louis

12. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Missouri

    • AMR Clinical, Kansas City

13. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Missouri

    • StudyMetrix Research, LLC, City of Saint Peters. 833-602-2368

14. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Missouri

    • StudyMetrix Research LLC, City of Saint Peters

15. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Missouri

    • StudyMetrix Research, City of Saint Peters. 636-387-5100
    • Clinvest Headlands Llc, Springfield

16. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. Run by T. John Winhusen, PhD. Registry number NCT06651177.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    1 site in Missouri

    • The Gibson Center for Behavioral Change, Cape Girardeau. 573-803-4158

17. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    1 site in Missouri

    • Clinical Research Consultants, Kansas City

18. Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

    Phase 2. Run by Washington University School of Medicine. Registry number NCT06976853.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 80, have Crohn's disease, BMI 25+.

    1 site in Missouri

    • Washington University School of Medicine, St Louis. 314-362-9044

19. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Missouri

    • Headlands Research, Springfield

20. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Missouri

    • StudyMetrix Research LLC, City of Saint Peters

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact